...
首页> 外文期刊>Alzheimer disease and associated disorders >SNP Variation in MicroRNA Biogenesis Pathway Genes as a New Innovation Strategy for Alzheimer Disease Diagnostics: A Study of 10 Candidate Genes in an Understudied Population From the Eastern Mediterranean
【24h】

SNP Variation in MicroRNA Biogenesis Pathway Genes as a New Innovation Strategy for Alzheimer Disease Diagnostics: A Study of 10 Candidate Genes in an Understudied Population From the Eastern Mediterranean

机译:MicroRNA生物发生途径基因中的SNP变异作为阿尔茨海默氏病诊断的一种新的创新策略:在来自东地中海的一个未充分研究的种群中的10个候选基因的研究

获取原文
获取原文并翻译 | 示例
           

摘要

Alzheimer disease (AD) is a common complex neurodegenerative disorder accounting for nearly 50% to 70% of dementias worldwide. Yet the current diagnostic options for AD are limited. New diagnostic innovation strategies focusing on novel molecules and pathways are sorely needed. In this connection, microRNAs (miRNAs) are conserved small noncoding RNAs that regulate posttranscriptional gene expression and are vital for neuronal development and its functional sustainability. Conceivably, biological pathways responsible for the biogenesis of miRNAs represent a veritable set of upstream candidate genes that can be potentially associated with the AD pathophysiology. Notably, whereas functional single-nucleotide polymorphisms (SNPs) in miRNA biogenesis pathway genes have been studied in other complex diseases, surprisingly, virtually no such study has been conducted on their relevance in AD. Moreover, novel diagnostics identified in easily accessible peripheral tissues such as the whole blood samples represent the initial entry or gateway points on the biomarker discovery critical path for AD. To the best of our knowledge, we report here the first association study of functional SNPs, as measured by real-time PCR in 10 upstream candidate genes critically situated on the miRNA biogenesis pathway, in a large sample of AD patients (N=172) and healthy controls (N=109) in a hitherto understudied world population from the Mersin region of the Eastern Mediterranean. We observed a significant association between 2 candidate genes and AD, TARBP2 rs784567 genotype and AD ((2)=6.292, P=0.043), and a trend for RNASEN rs10719 genotype ((2)=4.528, P=0.104) and allele (P=0.035). Functional SNP variations in the other 8 candidate genes (DGCR8, XPO5, RAN, DICER1, AGO1, AGO2, GEMIN3, and GEMIN4) did not associate with AD in our sample. Given the putative biological importance of miRNA biogenesis pathways, these emerging data can provide a new foundation to stimulate future debate and genetic investigations of AD, focusing on new molecular mechanisms such as miRNA biogenesis, particularly in accessible peripheral tissues for novel molecular diagnostics for dementia.
机译:阿尔茨海默氏病(AD)是一种常见的复杂性神经退行性疾病,约占全球痴呆症的50%至70%。然而,目前AD的诊断选择是有限的。迫切需要针对新型分子和途径的新诊断创新策略。就这一点而言,微小RNA(miRNA)是保守的非编码小RNA,可调节转录后基因的表达,对于神经元发育及其功能可持续性至关重要。可以想象,负责miRNA生物发生的生物学途径代表了一组真正的上游候选基因,这些基因可能与AD病理生理学潜在相关。值得注意的是,尽管已经在其他复杂疾病中研究了miRNA生物发生途径基因中的功能性单核苷酸多态性(SNP),但令人惊讶的是,实际上还没有关于其与AD相关性的研究。此外,在易于获取的外周组织(例如全血样品)中鉴定出的新颖诊断方法代表了AD的生物标志物发现关键路径上的初始入口或入口点。据我们所知,我们在此报告了第一例功能性SNP的关联研究,该研究通过实时PCR测定了大量AD患者(N = 172)中位于miRNA生物发生途径中关键的10个上游候选基因中。和迄今尚未研究的来自地中海东部梅尔辛地区的健康对照(N = 109)。我们观察到2个候选基因与AD,TARBP2 rs784567基因型和AD((2)= 6.292,P = 0.043)之间存在显着关联,以及RNASEN rs10719基因型((2)= 4.528,P = 0.104)和等位基因( P = 0.035)。其他8个候选基因(DGCR8,XPO5,RAN,DICER1,AGO1,AGO2,GEMIN3和GEMIN4)中的功能性SNP变异与我们样本中的AD不相关。鉴于miRNA生物发生途径的潜在生物学重要性,这些新兴数据可以为刺激AD的未来辩论和遗传研究提供新的基础,重点是诸如miRNA生物发生等新的分子机制,尤其是在可及的周围组织中,用于痴呆症的新型分子诊断。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号